Angelino Mark D. 4
4 · Generation Bio Co. · Filed Dec 17, 2020
Insider Transaction Report
Form 4
Angelino Mark D.
Chief Operating Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2020-12-15−5,301→ 118,460 totalExercise: $4.59Exp: 2028-04-01→ Common Stock (5,301 underlying) - Exercise/Conversion
Common Stock
2020-12-15$4.59/sh+5,301$24,332→ 350,938 total - Sale
Common Stock
2020-12-15$34.87/sh−4,401$153,463→ 346,537 total - Sale
Common Stock
2020-12-15$35.52/sh−900$31,968→ 345,637 total
Holdings
- 169,846(indirect: See Footnote)
Common Stock
Footnotes (5)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.39 to $35.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.41 to $35.84, inclusive.
- [F4]The securities are directly held by the Mark D. Angelino 2020 Qualified Annuity Trust, or the Trust. Mark D. Angelino is the settlor and trustee of the Trust, and the Trust is for the benefit of Elizabeth I., Emily A., John P., and Matthew R. Angelino. The reporting person may be deemed to beneficially own the shares of common stock owned by the Trust.
- [F5]The option to purchase 123,761 shares was granted on April 2, 2018. The shares underlying the option vest over four years, with 25% of the shares vested on April 2, 2019 and the remaining shares vesting in equal quarterly installments thereafter.